Molbio Diagnostics has raised ₹281.5 crore from major anchor investors, including Goldman Sachs and BlackRock, ahead of its ₹940-crore public issue opening today. With a price band of ₹768–₹807, the company aims to use the proceeds to expand its research and manufacturing base. Investors are keeping a close watch on the company's valuation and the execution of its growth plans for the Truenat platform.
Molbio Diagnostics, a key player in the point-of-care molecular diagnostics space, has kicked off its initial public offering (IPO) today, August 10, 2026. The company successfully raised ₹281.5 crore from 33 institutional investors through its anchor book. Shares were allotted to these participants at the upper price band of ₹807, signaling interest from major global and domestic names like Goldman Sachs, BlackRock, and HDFC Mutual Fund. The International Finance Corporation (IFC) also returned to India's IPO market by participating in this round.
The public issue, totaling ₹940 crore, consists of a fresh issue of shares worth ₹200 crore and an offer for sale (OFS) of approximately ₹740 crore. In an offer for sale, existing shareholders sell their stakes, meaning the company does not directly receive that cash. However, the ₹200 crore raised through the fresh issue is intended for specific growth projects. The company plans to use this money to build a new research and development facility and invest in machinery and equipment for its manufacturing units in Goa and Visakhapatnam. This capital spending is designed to boost the company’s capacity to produce its flagship 'Truenat' test kits.
At the core of the business is the Truenat platform, which allows for fast molecular testing outside of traditional large labs. This business advantage has allowed the company to grow in the diagnostics space. However, investors often look at how much a company earns relative to its share price, which is measured by the P/E ratio. With a P/E ratio hovering around 57, the stock’s valuation is on the higher side compared to some market standards, reflecting market expectations for future growth. Whether the company can justify this valuation will depend on its ability to increase revenue and protect its profit margins in a competitive sector.
Beyond valuation, there are execution risks to monitor. The company depends heavily on the recurring sales of its Truenat kits and the continued adoption of its testing platform. If the expansion of its manufacturing or research facilities faces any delays, it could impact the company's ability to meet market demand. Additionally, while the company has seen consistent growth, maintaining that pace while managing costs in the highly competitive diagnostics sector remains a challenge.
The IPO subscription process runs from August 10 to August 12, 2026, with the shares tentatively expected to list on the stock exchanges on August 17, 2026. Going forward, investors may track the subscription numbers, management's plans for deploying the new capital, and any updates regarding the demand for the Truenat platform in the coming quarters.